annie-zoe: Colloid Co-hydration and Vasoconstrictor Infusion for Prevention of Hypotension During Cesarean Section

Sponsor
Aretaieion University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04404946
Collaborator
(none)
120
1
3
12.3
9.8

Study Details

Study Description

Brief Summary

This will be a double-blind randomized study, aiming at investigating a fixed rate phenylephrine infusion versus a fixed rate norepinephrine infusion versus placebo in combination with co-hydration with colloids for the prevention of maternal hypotension in elective cesarean section

Condition or Disease Intervention/Treatment Phase
  • Other: phenylephrine infusion
  • Other: norepinephrine infusion
  • Other: placebo infusion
N/A

Detailed Description

Neuraxial techniques are the anesthetic techniques of choice in contemporary obstetric anesthesia practice, with a definitive superiority as compared to general anesthesia, since, by their use, serious complications involving the airway can be avoided.Spinal anesthesia has become the favorable technique for both elective and emergency cesarean section due to a quick and predictable onset of action, however, it can be frequently complicated by hypotension, with incidence exceeding 80% occasionally.

The aim of the current randomized controlled double-blinded trial was to compare the effect of a fixed-rate norepinephrine infusion versus a fixed-rate phenylephrine infusion versus placebo in parturients subjected to elective cesarean section under combined spinal-epidural anesthesia. All parturients will also receive colloid co-hydration.

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Colloid Co-hydration and Vasoconstrictor Infusion for Prevention of Postspinal Hypotension During Elective Cesarean Section. A Comparative Study
Actual Study Start Date :
May 23, 2020
Actual Primary Completion Date :
May 31, 2021
Actual Study Completion Date :
May 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: phenylephrine infusion

fixed-rate phenylephrine infusion

Other: phenylephrine infusion
in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
Other Names:
  • medication used for blood pressure maintenance
  • Active Comparator: norepinephrine infusion

    fixed-rate norepinephrine infusion

    Other: norepinephrine infusion
    in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
    Other Names:
  • medication used for blood pressure maintenance
  • Placebo Comparator: placebo infusion

    normal saline infusion

    Other: placebo infusion
    in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
    Other Names:
  • medication used for blood pressure maintenance
  • Outcome Measures

    Primary Outcome Measures

    1. incidence of bradycardia [intraoperative]

      any incidence of maternal bradycardia (heart rate<60/min) will be recorded

    2. incidence of hypotension [intraoperative]

      any occurence of hypotension (systolic blood pressure<80% of baseline) throughout the operation will be recorded

    Secondary Outcome Measures

    1. need for vasoconstrictor [intraoperative]

      any need for vasoconstrictor during the operation will be recorded

    2. type of vasoconstrictor administered [intraoperative]

      phenylephrine versus ephedrine

    3. number of bolus doses of vasoconstrictor administered [intraoperative]

      number of interventions to maintain systolic blood pressure within the set limits will be recorded

    4. total dose of vasoconstrictor administered [intraoperative]

      total dose in mg for ephedrine or μg for phenylephrine administered

    5. incidence of hypertension [intraoperative]

      any incidence of systolic blood pressure>120% of baseline will be recorded

    6. need for atropine [intraoperative]

      any need for atropine during the operation because of bradycardia will be recorded

    7. modification or cessation of the infusion [intraoperative]

      any requirement for modification or cessation of the infusion due to reactive hypertension or bradycardia will be recorded

    8. incidence of nausea/vomiting [intraoperative]

      any occurence of nausea and/or vomiting during the operation will be recorded

    9. Neonatal Apgar score at 1 minutes [1 minute post delivery]

      Neonatal Apgar score will be recorded at 1 minutes after delivery. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low and cause for immediate resuscitative efforts.

    10. Neonatal Apgar score at 5 minutes [5 minutes post delivery]

      Neonatal Apgar score will be recorded at 5 minutes after delivery. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. Scores 7 and above are generally normal; 4 to 6, fairly low; and 3 and below are generally regarded as critically low and cause for immediate resuscitative efforts.

    11. neonatal blood gases [1 minute post delivery]

      fetal cord blood analysis will be performed immediately post-delivery

    12. glucose in neonatal blood [1 minute post delivery]

      glucose will be measured in the cord blood gas sample taken immediately post-delivery

    13. adrenaline in neonatal blood [5 minutes post delivery]

      an amount of the umbilical artery cord blood sampled from every neonate will be sent for lab measurements

    14. noradrenaline in neonatal blood [5 minutes post delivery]

      an amount of the umbilical artery cord blood sampled from every neonate will be sent for lab measurements

    Other Outcome Measures

    1. cardiac output [intraoperative]

      cardiac output via non-invasive device (Nexfin) will be measured intraoperatively

    2. stroke volume [intraoperative]

      stroke volume via non-invasive device (Nexfin) will be measured intraoperatively

    3. systemic vascular resistance [intraoperative]

      systemic vascular resistance via non-invasive device (Nexfin) will be measured intraoperatively

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 48 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • adult parturients, American Society of Anesthesiologists (ASA) I-II,

    • singleton gestation>37 weeks

    • elective cesarean section

    Exclusion Criteria:
    • Body Mass Index (BMI) >40 kg/m2

    • Body weight <50 kg

    • Body weight>100 kg

    • height<150 cm

    • height>180 cm

    • multiple gestation

    • fetal abnormality

    • fetal distress

    • active labor

    • cardiac disease

    • pregnancy-induced hypertension

    • thrombocytopenia

    • coagulation abnormalities

    • use of antihypertensive medication during pregnancy

    • communication or language barriers

    • lack of informed consent

    • contraindication for regional anesthesia

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Aretaieion University Hospital Athens Greece 115 28

    Sponsors and Collaborators

    • Aretaieion University Hospital

    Investigators

    • Principal Investigator: Kassiani Theodoraki, PhD, DESA, Aretaieion University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dr Kassiani Theodoraki, Professor of Anesthesiology, Aretaieion University Hospital
    ClinicalTrials.gov Identifier:
    NCT04404946
    Other Study ID Numbers:
    • 196/25-02-2020
    First Posted:
    May 28, 2020
    Last Update Posted:
    Jun 15, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 15, 2021